|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with neovascular (wet) age-related macular degeneration.|
|Rapid review commissioned||29/08/2022|
|Rapid review completed||04/10/2022|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab compared with the current standard of care.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.